BR112014018795B1 - Compostos derivados de 1h-pirrolo[2,3-b]piridina, composição farmacêutica e seu uso como inibidores de cinase - Google Patents

Compostos derivados de 1h-pirrolo[2,3-b]piridina, composição farmacêutica e seu uso como inibidores de cinase Download PDF

Info

Publication number
BR112014018795B1
BR112014018795B1 BR112014018795-9A BR112014018795A BR112014018795B1 BR 112014018795 B1 BR112014018795 B1 BR 112014018795B1 BR 112014018795 A BR112014018795 A BR 112014018795A BR 112014018795 B1 BR112014018795 B1 BR 112014018795B1
Authority
BR
Brazil
Prior art keywords
pyridin
pyrrolo
benzyl
pyrazol
carboxylic
Prior art date
Application number
BR112014018795-9A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014018795A2 (pt
Inventor
Stephen Stokes
Christoper John Graham
Stuart Christopher Ray
Emma Jayne Stefaniak
Original Assignee
Vernalis (R&D) Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis (R&D) Ltd filed Critical Vernalis (R&D) Ltd
Publication of BR112014018795A2 publication Critical patent/BR112014018795A2/pt
Publication of BR112014018795B1 publication Critical patent/BR112014018795B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112014018795-9A 2012-01-30 2013-01-30 Compostos derivados de 1h-pirrolo[2,3-b]piridina, composição farmacêutica e seu uso como inibidores de cinase BR112014018795B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1201566.5A GB201201566D0 (en) 2012-01-30 2012-01-30 New chemical compounds
GB1201566.5 2012-01-30
PCT/GB2013/050212 WO2013114113A1 (en) 2012-01-30 2013-01-30 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors

Publications (2)

Publication Number Publication Date
BR112014018795A2 BR112014018795A2 (pt) 2017-07-04
BR112014018795B1 true BR112014018795B1 (pt) 2020-09-29

Family

ID=45876325

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014018795-9A BR112014018795B1 (pt) 2012-01-30 2013-01-30 Compostos derivados de 1h-pirrolo[2,3-b]piridina, composição farmacêutica e seu uso como inibidores de cinase

Country Status (21)

Country Link
US (3) US10000481B2 (enExample)
EP (1) EP2809670B1 (enExample)
JP (1) JP6199316B2 (enExample)
CN (4) CN107011341A (enExample)
AU (1) AU2013213954B2 (enExample)
BR (1) BR112014018795B1 (enExample)
CA (1) CA2862940C (enExample)
DK (1) DK2809670T3 (enExample)
EA (1) EA026657B1 (enExample)
ES (1) ES2637340T3 (enExample)
GB (1) GB201201566D0 (enExample)
HK (1) HK1200447A1 (enExample)
HU (1) HUE035332T2 (enExample)
IL (1) IL233595B (enExample)
IN (1) IN2014DN06104A (enExample)
MX (1) MX352927B (enExample)
NZ (1) NZ627361A (enExample)
PL (1) PL2809670T3 (enExample)
PT (1) PT2809670T (enExample)
WO (1) WO2013114113A1 (enExample)
ZA (1) ZA201405070B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201201566D0 (en) * 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds
AR090789A1 (es) * 2012-04-23 2014-12-10 Genentech Inc Intermediarios y procesos para la preparacion de compuestos
JP6463758B2 (ja) * 2013-08-22 2019-02-06 ジェネンテック， インコーポレイテッド 化合物の調製方法
CN104829609B (zh) * 2014-02-11 2016-08-03 北大方正集团有限公司 取代的吡啶并嘧啶化合物及其制备方法和应用
MA41559A (fr) * 2015-09-08 2017-12-26 Taiho Pharmaceutical Co Ltd Composé de pyrimidine condensé ou un sel de celui-ci
US10032914B2 (en) * 2015-10-20 2018-07-24 Taiwan Semiconductor Manufacturing Co., Ltd. Semiconductor device and manufacturing method thereof
HRP20200352T1 (hr) 2016-02-23 2020-06-12 Taiho Pharmaceutical Co., Ltd. Novi kondenzirani pirimidinski spoj ili njegova sol
CA3073375A1 (en) 2017-08-21 2019-02-28 Taiho Pharmaceutical Co., Ltd. Fusion protein of dctn1 protein with ret protein
WO2020150417A2 (en) 2019-01-17 2020-07-23 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
CN111518096B (zh) 2019-02-02 2022-02-11 江苏威凯尔医药科技有限公司 两面神激酶jak家族抑制剂及其制备和应用
KR20220042159A (ko) 2019-08-01 2022-04-04 인테그랄 바이오사이언스 피브이티. 엘티디. 키나제 억제제로서의 헤테로사이클릭 화합물 및 이의 용도
IT202000005527A1 (it) * 2020-03-16 2021-09-16 Univ Degli Studi Di Trento Trattamento terapeutico di cromatinopatie
US20230271941A1 (en) 2020-07-15 2023-08-31 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
TW202216685A (zh) * 2020-07-15 2022-05-01 美商Ｉｆｍ Ｄｕｅ有限公司 用於治療與sting活性相關的病狀之化合物及組合物
US20230365553A1 (en) * 2020-07-15 2023-11-16 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2022150585A1 (en) 2021-01-08 2022-07-14 Ifm Due, Inc. Heterobicyclic compounds having an urea or analogue and their compositions for treating conditions associated with sting activity
CN118613473A (zh) * 2022-01-12 2024-09-06 艾福姆德尤股份有限公司 用于治疗与sting活性相关的病症的化合物和组合物
CN116554170A (zh) * 2023-04-26 2023-08-08 上海大学 4-氟-7-氮杂吲哚的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1012976A (en) * 1909-03-25 1911-12-26 Adolf Bordt Adding-machine.
WO2003028724A1 (en) * 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
US7531553B2 (en) * 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
PH12012501891A1 (en) * 2003-11-21 2013-09-02 Array Biopharma Inc Akt protein kinase inhibitors
WO2009089352A1 (en) * 2008-01-08 2009-07-16 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
JP5386508B2 (ja) * 2008-01-22 2014-01-15 ヴァーナリス アールアンドディー リミテッド インドリル−ピリドン誘導体類
AR071717A1 (es) 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
KR20110015699A (ko) 2008-06-11 2011-02-16 제넨테크, 인크. 디아자카르바졸 및 사용 방법
CN102573994B (zh) * 2009-08-06 2015-06-24 默克专利有限公司 双环脲化合物
EP2571361A4 (en) * 2010-05-19 2013-11-13 Univ North Carolina PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
GB201201566D0 (en) * 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds

Also Published As

Publication number Publication date
EA026657B1 (ru) 2017-05-31
CA2862940C (en) 2021-09-14
HK1200447A1 (en) 2015-08-07
JP2015505555A (ja) 2015-02-23
IL233595B (en) 2018-05-31
MX2014009112A (es) 2014-11-10
CA2862940A1 (en) 2013-08-08
NZ627361A (en) 2016-07-29
AU2013213954A1 (en) 2014-08-07
PT2809670T (pt) 2017-08-23
WO2013114113A1 (en) 2013-08-08
US10000481B2 (en) 2018-06-19
EP2809670B1 (en) 2017-05-17
CN107011341A (zh) 2017-08-04
CN106866658B (zh) 2021-04-27
CN106866658A (zh) 2017-06-20
US10889582B2 (en) 2021-01-12
CN104203948A (zh) 2014-12-10
ES2637340T3 (es) 2017-10-11
ZA201405070B (en) 2016-03-30
BR112014018795A2 (pt) 2017-07-04
EA201491376A1 (ru) 2015-01-30
US20180362526A1 (en) 2018-12-20
PL2809670T3 (pl) 2017-10-31
US20210206762A1 (en) 2021-07-08
JP6199316B2 (ja) 2017-09-20
AU2013213954B2 (en) 2016-02-25
CN111484493A (zh) 2020-08-04
IL233595A0 (en) 2014-08-31
US20150011533A1 (en) 2015-01-08
EP2809670A1 (en) 2014-12-10
HUE035332T2 (en) 2018-05-02
DK2809670T3 (en) 2017-08-28
GB201201566D0 (en) 2012-03-14
MX352927B (es) 2017-12-14
IN2014DN06104A (enExample) 2015-08-14

Similar Documents

Publication Publication Date Title
BR112014018795B1 (pt) Compostos derivados de 1h-pirrolo[2,3-b]piridina, composição farmacêutica e seu uso como inibidores de cinase
TWI650319B (zh) 用於調節表皮生長因子受體（ｅｇｆｒ）活性之化合物及組合物
ES2551592T3 (es) Pirazolo[1,5-a]piridinas como inhibidores de TRK
ES2363831T3 (es) [2,6]naftiridinas útiles como inhibidores de quinasas proteínicas.
BRPI0708016A2 (pt) composto ou um sal, solvato ou n-óxido do mesmo, composição farmacêutica, uso de um composto ou um sal, solvato ou n-óxido do mesmo, e, método para o tratamento e/ou prevenção de distúrbios
TW200811173A (en) Pyrazoloquinolones are potent PART inhibitors
BRPI0906495B1 (pt) compostos derivados de indolil-piridona e composição farmacêutica
BR112021001618A2 (pt) antagonistas tlr7/8 e usos dos mesmos
AU2019392524B2 (en) Heteroaromatic compounds as vanin inhibitors
BR112016001080B1 (pt) Compostos de isoindolina ou isoquinolina, um processo para sua preparação e composições farmacêuticas contendo-os
BRPI0620196A2 (pt) composto, processo para a preparaÇço do mesmo, composiÇço farmacÊutica, uso de um composto, e, mÉtodos para a produÇço de um efeito antibacteriano em um animal de sangue quente, para a inibiÇço de dna girase e/ou topoisomerase iv bacteriana em um animal de sangue quente e para o tratamento de uma infecÇço bacteriana em um animal de sangue quente
CN104203958B (zh) 二环杂环衍生物、其制备及治疗用途
WO2021020585A1 (ja) 複素環化合物
CN115666553A (zh) Tlr2调节剂化合物及其药物组合物和用途
HK1240217B (zh) 1h-吡咯并[2,3-b]吡啶衍生物及它们作为激酶抑制剂的用途
HK40025567A (en) 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors
HK1240217A1 (en) 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors
HK1240227A1 (en) 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors
WO2022028556A1 (zh) Cdk9抑制剂及其用途
BR112018076327B1 (pt) Compostos como inibidores de autotaxinas e composições farmacêuticas compreendendo os mesmos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/01/2013, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 13A ANUIDADE.